| STUDY |
PARP inhibitor |
PHASE |
STATUS |
| Olaparib for patients with recurrent BRCA deficient ovarian cancer |
olaparib |
Phase 2 |
Withdrawn |
| AZD2281 Plus Carboplatin to treat breast and ovarian cancer |
AZD2281 |
Phase 1 |
Recruiting |
| A study to assess the safety and pharmacokinetics of an inhibitor of Poly-ADP-Ribose Polymerase-1 (PARP) |
AZD2281 |
Phase 1 |
Active, not recruiting |
| A single-arm study evaluating carboplatin/gemcitabine in combination with BSI-201 in patients with platinum-Sensitive recurrent ovarian cancer |
Iniparib |
Phase 2 |
Completed |
| A single-arm study evaluating carboplatin/gemcitabine in combination with BSI-201 in patients with platinum-resistant recurrent ovarian cancer |
Iniparib |
Phase 2 |
Completed |
| An open-label, multicenter, phase 1/2 study of Poly(ADP-ribose) Polymerase (PARP) Inhibitor E7449 as single agent in subjects with advanced solid tumors or with B-cell malignancies and in combination with Temozolomide (TMZ) or with Carboplatin and Paclitaxel in subjects with advanced solid tumors |
E7449 |
Phase 1, Phase 2 |
Recruiting |
| Study to assess the efficacy and safety of a PARP Inhibitor for the treatment of BRCA-positive advanced ovarian cancer |
AZD2281 |
Phase 2 |
Completed |
| Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in treating patients with locally advanced or metastatic breast cancer or advanced ovarian cancer |
Rucaparib |
Phase 2 |
Recruiting |
| Olaparib in combination with carboplatin for refractory or recurrent women's cancers |
Olaparib |
Phase 1 |
Recruiting |
| Study to assess the safety and tolerability of a parp inhibitor in combination with carboplatin and/or paclitaxel |
AZD2281 |
Phase 1 |
Active, not recruiting |
| Dose-finding study comparing efficacy and safety of a PARP inhibitor against Doxil in BRCA+ve advanced ovarian cancer |
AZD2281 |
Phase 2 |
Active, not recruiting |
| A study of MK4827 in participants with advanced solid tumors or hematologic malignancies (MK-4827-001 AM8) |
MK-4827 |
Phase 1 |
Completed |
| Study to compare the efficacy and safety of Olaparib when given in combination with Carboplatin and Paclitaxel, compared with Carboplatin and Paclitaxel in patients with advanced ovarian cancer |
Olaparib |
Phase 2 |
Active, not recruiting |
| Phase I of BKM120/Olaparib for triple negative breast cancer or high grade serous ovarian cancer |
BKM120 and Olaparib |
Phase 1 |
Recruiting |
| Veliparib and Topotecan Hydrochloride in treating patients with solid tumors, relapsed or refractory ovarian cancer, or primary peritoneal cancer |
Veliparib |
Phase 1, Phase 2 |
Recruiting |
| Phase II study of AZD2281 in patients with known BRCA mutation status or recurrent high grade ovarian cancer or Patients with known BRCA mutation status/triple neg breast cancer |
AZD2281 |
Phase 2 |
Active, not recruiting |
| Veliparib and pegylated liposomal doxorubicin hydrochloride in treating patients with recurrent ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer |
Veliparib |
Phase 1 |
Recruiting |
| A study of Oral Rucaparib in Patients with a Solid Tumor (Phase I) or with gBRCA Mutation Ovarian Cancer (Phase II) |
Rucaparib |
Phase 1, Phase 2 |
Recruiting |
| Veliparib Monotherapy for Relapsed Ovarian Cancer with BRCA Mutation |
Veliparib |
Phase 1, Phase 2 |
Recruiting |
| Olaparib treatment in BRCA mutated ovarian cancer Patients After Complete or Partial Response to Platinum Chemotherapy |
Olaparib 300 mg tablets |
Phase 3 |
Not yet recruiting |
| Olaparib Monotherapy in Patients with BRCA mutated ovarian cancer following first line platinum based chemotherapy |
Olaparib 300 mg tablets |
Phase 3 |
Not yet recruiting |
| Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer |
AZD2281 |
Phase 2 |
Completed |
| A study of Rucaparib in patients with platinum-sensitive, relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (ARIEL2) |
Oral Rucaparib |
Phase 2 |
Not yet recruiting |
| Study of BMN 673, a PARP Inhibitor, in Patients with Advanced or Recurrent Solid Tumors |
BMN 673 |
Phase 1 |
Recruiting |
| ABT-888 with Cyclophosphamide in Refractory BRCA-Positive ovarian, primary peritoneal or ovarian high-grade serous carcinoma, fallopian tube cancer, triple-negative breast cancer, and low-grade non-hodgkin's lymphoma |
ABT-888 |
Phase 2 |
Active, not recruiting |
| A Phase I study of ABT-888 in combination with Temozolomide in Cancer Patients |
ABT-888 |
Phase 1 |
Completed |
| Veliparib, Cisplatin, and Vinorelbine Ditartrate in treating patients with Recurrent and/or Metastatic Breast Cancer |
Veliparib |
Phase 1 |
Recruiting |
| Single arm study of BSI-201 in Patients with BRCA-1 or BRCA-2 associated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer |
Iniparib |
Phase 2 |
Completed |
| Veliparib in treating patients with malignant solid tumors that did not respond to previous therapy |
Veliparib |
Phase 1 |
Recruiting |
| Veliparib and Floxuridine in treating patients with metastatic epithelial ovarian, primary peritoneal cavity, or fallopian tube cancer |
Veliparib |
Phase 1 |
Recruiting |
| Veliparib in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer |
Veliparib |
Phase 2 |
Active, not recruiting |
| Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in treating patients with newly diagnosed Stage II, Stage III, or Stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer |
Veliparib |
Phase 1 |
Recruiting |
| Cediranib and Olaparib in combination for recurrent ovarian or Triple-Negative Breast Cancer |
Olaparib, Cediranib |
Phase 1, Phase 2 |
Active, not recruiting |
| Open label study to assess efficacy and safety of Olaparib in confirmed genetic BRCA1 or BRCA2 mutation pats |
Olaparib |
Phase 2 |
Active, not recruiting |
